Jasdave Chahal
Fondatore presso Tiba Biotech LLC
Profilo
Jasdave Chahal is a Chief Scientist and founder of Tiba Biotech LLC, which is founded in 2018.
He is currently a Venture Partner at incTANK Inc. Mr. Chahal received his undergraduate degree from the University of Ottawa in 2006 and his doctorate from Princeton University in 2012.
Posizioni attive di Jasdave Chahal
Società | Posizione | Inizio |
---|---|---|
Tiba Biotech LLC
Tiba Biotech LLC BiotechnologyHealth Technology Tiba Biotech LLC is a company that specializes in advancing the RNA medicine field with an improved approach to nucleic acid delivery. The company is based in Cambridge, MA. The company has developed a fully biodegradable nanoparticle delivery platform for safer vaccines and therapeutics, as well as a computational RNA design for more potent gene expression. The company's goal is to achieve better patient outcomes through rational design, from gene to delivery method beyond vaccines. The company was founded in 2017 by Christian Mandl, Karl H. Ruping, Jasdave Chahal. Karl H. Ruping has been the CEO since 2017. | Fondatore | 01/01/2018 |
incTANK Inc
incTANK Inc Investment ManagersFinance incTANK Inc (incTANK) is a venture capital firm founded in 1999 by Karl H. Ruping. The firm is headquartered in the Cambridge, Massachusetts. | Investitore di Private Equity | - |
Formazione di Jasdave Chahal
University of Ottawa | Undergraduate Degree |
Princeton University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
incTANK Inc
incTANK Inc Investment ManagersFinance incTANK Inc (incTANK) is a venture capital firm founded in 1999 by Karl H. Ruping. The firm is headquartered in the Cambridge, Massachusetts. | Finance |
Tiba Biotech LLC
Tiba Biotech LLC BiotechnologyHealth Technology Tiba Biotech LLC is a company that specializes in advancing the RNA medicine field with an improved approach to nucleic acid delivery. The company is based in Cambridge, MA. The company has developed a fully biodegradable nanoparticle delivery platform for safer vaccines and therapeutics, as well as a computational RNA design for more potent gene expression. The company's goal is to achieve better patient outcomes through rational design, from gene to delivery method beyond vaccines. The company was founded in 2017 by Christian Mandl, Karl H. Ruping, Jasdave Chahal. Karl H. Ruping has been the CEO since 2017. | Health Technology |
- Borsa valori
- Insiders
- Jasdave Chahal